Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos


In patients requiring secondary CVD prevention, P2Y12 inhibitor monotherapy conferred reduced risk for major adverse CV events compared with aspirin monotherapy without raising risk for bleeding, researchers reported.The researchers conducted a meta-analysis of nine trials — five comparing clopidogrel with aspirin and four comparing ticagrelor (Brilinta, AstraZeneca) with aspirin —